Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (Pharmetrics)
N/A
18 Years
64 Years
18 Years
64 Years
Not Enrolling
Both
Carcinoma, Renal Cell
Both
Carcinoma, Renal Cell
Trial Information
Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (Pharmetrics)
Inclusion Criteria:
- two or more medical encounters with a diagnosis of kidney cancer (ICD-9-CM 189.0) or
malignant neoplasm of the renal pelvis (189.1), and
- two or more medical encounters with a diagnosis of distant secondary malignant
neoplasm (ICD-9-CM 197.XX-199.0, excluding 198.0 [kidney metastasis]) on different
days <120 days apart (the date of the earliest such encounter will be designated the
"index date").
Exclusion Criteria:
- evidence of receipt of chemotherapeutic agents indicated or used in the treatment of
advanced TCC, or
- evidence of cystoscopy, biopsy of the bladder, or radical cystectomy
- evidence of any other primary cancer
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Retrospective
Outcome Measure:
New and existing claims of metastatic renal cell carcinoma across multiple years
Outcome Description:
Identifying new and existing claims (based on claims based case-ascertainment algorithm) of metastatic renal cell carcinoma across multiple years
Outcome Time Frame:
2000 - 2009 (up to 10 years)
Safety Issue:
No
Principal Investigator
GSK Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
GlaxoSmithKline
Authority:
United States: No Health Authority
Study ID:
114866
NCT ID:
NCT01381601
Start Date:
March 2011
Completion Date:
October 2011
Related Keywords:
- Carcinoma, Renal Cell
- retrospective database analysis
- economic burden
- Carcinoma
- Carcinoma, Renal Cell
Name | Location |
|---|
